MTT Cell Proliferation Assay

• Use cultured cells in appropriate complete culture medium, the test treatment or stimulus, untreated/vehicle control medium, MTT reagent, and a formazan-solubilizing solvent.
• DMSO has been reported as an effective solvent for dissolving MTT formazan, particularly when residual medium remains in wells; other published protocols also used solubilization approaches after MTT conversion^[5][6][7].

• MTT, chemically 3-^{[4][5-dimethylthiazol-2-yl]}-2,5-diphenyl tetrazolium bromide, is the assay dye and is converted by living cells into formazan crystals.
• Use sterile cell-culture plates or microtitre trays, standard cell-culture equipment, and a multiwell scanning spectrophotometer or ELISA plate reader.
• The original and modified MTT methods were designed for microtitre-format colorimetric reading using a multiwell spectrophotometer^[1][7].

• Seed cells into microtitre wells at densities that will remain within the linear response range of the assay at the planned endpoint.
Published optimization studies emphasize that cell density, culture medium, MTT concentration, MTT exposure time, and treatment-specific metabolic effects should be established for each cell line or treatment before interpreting MTT absorbance as viable cell number^[5][6].

• Prepare treatment groups with untreated or vehicle controls and, when testing colored, reducing, or metabolically active compounds, include cell-free wells containing treatment plus MTT to check chemical or optical interference.
Anticancer drugs and other compounds have been reported to interact with MTT or alter MTT readout independently of true viable cell number^{[8][9][10][11]}.

• After the planned treatment or proliferation interval, add MTT to the cells and incubate long enough for living cells to generate visible formazan; published MTT protocols and optimization papers report that MTT concentration and exposure time must be empirically optimized because excessive or unsuitable conditions can distort calculated cell number^[2][6].

• At the end of MTT incubation, dissolve the insoluble formazan before absorbance measurement.
DMSO was reported to dissolve formazan effectively, and the solubilization method should be kept constant across all wells because solvent choice and residual medium can affect the measured signal^[5][6].

• Measure absorbance with a plate reader at the wavelength validated for the solvent and protocol.
Published MTT methods commonly quantify dissolved formazan spectrophotometrically, and pH can alter the MTT-formazan absorption spectrum, so pH and solvent conditions should remain consistent across the plate^[1][7][12].

• Subtract blank or cell-free background values from sample wells, then express results relative to untreated or vehicle controls when comparing treatment effects.
Interpret higher absorbance as higher MTT-reducing activity only within the experimentally validated linear range, because altered metabolism, mitochondrial activity, cell-cycle redistribution, or compound interference can cause false-high or false-low viability estimates^{[6][9][10][11]}.

• Use biological replicates from independent cultures and technical replicate wells when estimating treatment effects, and confirm key conclusions with an orthogonal assay when the treatment is expected to alter metabolism or directly interact with tetrazolium chemistry.
Published studies show that MTT can disagree with direct cell counting, clonogenic assays, flow-cytometric cell-cycle analysis, or other viability measures under specific drug or metabolic conditions^{[8][9][10][11]}.

Problem: MTT absorbance appears higher despite reduced cell number or expected growth inhibition.

• Possible Cause: The test compound may increase mitochondrial or cellular reducing activity, alter cell-cycle state, or uncouple oxidative metabolism, causing overestimation of viable cell number.
• Literature-supported Solution: Compare MTT results with direct cell counting or another independent proliferation/viability readout, and avoid relying on MTT alone for compounds known or suspected to alter mitochondrial activity or uncoupling^[9][10].

Problem: MTT signal changes in wells without cells.

• Possible Cause: The test compound may chemically interact with MTT or contribute absorbance that is unrelated to viable cells.
• Literature-supported Solution: Include cell-free wells containing the test compound and MTT, and remove or reinterpret conditions showing compound-MTT interference^[11].

Problem: Weak or inconsistent signal across wells.

• Possible Cause: Cell density, MTT exposure, culture medium, or treatment conditions may be outside the optimized assay range.
• Literature-supported Solution: Establish cell-density linearity and optimize MTT concentration, exposure time, culture medium condition, and assay timing for each cell line and treatment before running definitive experiments^[5][6].

Problem: Results differ from direct cell counts or other viability assays.

• Possible Cause: MTT measures cellular reducing activity rather than cell number alone, and treatments can change metabolism without proportional changes in viable cell number.
• Literature-supported Solution: Treat MTT as a metabolic viability surrogate and confirm discordant or high-impact findings with an independent assay such as direct cell counting, clonogenic assay, LDH release, flow cytometry, or another non-tetrazolium method^[8][9][10].